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Abstract 
Background: Suboptimal glycaemic control, 
measured by glycosylated haemoglobin (HbA1c), 
increases the risk for long-term complications in 
Type 1 diabetes mellitus (T1DM). 
Aims and objectives: 
 To calculate and compare glycaemic control in 
children with T1DM in Malta during the period 
2013 to 2014.  
 To identify any need for changing way services 
are structured and delivered. 
Methods:  An estimated 96% of all children 
with T1DM less than 16 years of age in Malta are 
cared for by the same paediatric diabetes team, 
based at the main state hospital. The average HbA1c 
of all measurements taken every 3 months by HbA1c 
analyser was calculated for each patient and these 
results were validated by annual laboratory 
measurement of HbA1c from venous samples. 
Results: Overall, 43.8% of participants in 2013 
and 49.6% of participants in 2014 achieved an 
HbA1c target of < 7.5%. The mean HbA1c in 2013 
was 7.69±0.16% and in 2014 7.67±0.17%. A higher 
proportion of patients in the younger age-group 
achieved an HbA1c target of <7.5%. The patients 
most likely to have a higher HbA1c were in the older 
age-groups.  
 
 
 
Conclusion: Glycaemic control achieved in 
Malta in children aged < 16 years with T1DM was 
stable over the two years analysed. Our data is 
comparable, or slightly better, to that achieved in 
other European countries. However, there is always 
room for improvement, as Swedish data have 
shown. Multidisciplinary team meetings could be 
one way to address those patients not achieving 
adequate control. 
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Introduction 
Suboptimal glycaemic control in persons with 
Type 1 Diabetes Mellitus (T1DM) increases the risk 
for long-term complications.1-3 The HbA1c is the 
best indicator of long-term diabetes control. Every 
1.0% point decrease in HbA1c can reduce the risk of 
microvascular complications by 40%.1 Intensive 
glycaemic control has been unequivocally proven to 
substantially lower the incidence of diabetes-related 
complications and extend life-expectancy.4 
International treatment guidelines recommend 
glycaemic targets to preserve health and reduce the 
risk of complications5-6 however, many young 
people with T1DM fail to achieve these targets.7-10  
This audit, comparing glycaemic control in 
individuals less than 16 years of age with T1DM in 
2013 and 2014, is the first report of its kind in 
Malta. It is the first step to compile annual data 
about T1DM in children in Malta, and provides a 
facility for monitoring and benchmarking of 
services and an opportunity to develop more 
effective treatment strategies.  
 
Aim 
 To examine current levels of glycaemic control 
in young people with Type 1 Diabetes in Malta 
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and compare our results  with similar European 
data. 
 To calculate the proportion of young people 
with Type 1 Diabetes in Malta who are 
attaining HbA1c goals of < 7.5% (< 
58mmol/mol) as recommended by the 
International Society for Paediatric and 
Adolescent Diabetes (ISPAD) and the 
American Diabetes Association.5-6  
 To  identify any need for changing the way 
services are structured and delivered  with the 
ultimate aim of improving quality of care, 
glycaemic control and outcomes for children 
and adolescents with T1DM in Malta. 
 
Methods 
Study design and population 
An estimated 96% of children with T1DM in 
Malta are seen by the paediatric diabetes team on a 
regular basis at the main state hospital. 
Demographic and clinical data of all patients newly 
diagnosed with T1DM are collected on a Microsoft 
Excel® spreadsheet and up-dated annually with new 
information such as average annual HbA1c and 
Body Mass Index. In 2013, a point of care HbA1c 
analyser (Siemens DCA Vantage®) was made 
available to the paediatric diabetes team, so that 
HbA1c could be measured at each clinic visit, every 
3 months. These results were validated by annual 
laboratory measurements of HbA1c from venous 
samples. 
The average HbA1c ±95% CI of all the 
measurements taken in 2013 and 2014 was used in 
this study to assess overall glycaemic control. 
Multiple HbA1c measurements have been used on 
each patient to give a more accurate assessment of 
diabetes control over the entire year of care, and to 
bring the analysis in line with other international 
reporting audits and registries, making 
benchmarking more representative. HbA1c values 
using the Diabetes Control and Complications Trial 
(DCCT) aligned measures of percentage (%) were 
converted to the newer IFCC-standardised measures 
in mmol/mol using the formula: IFCC (mmol/mol) 
= (10.93 x DCCT (%)) - 23.50.  
 
Results 
Participants 
In 2013, there were 137 children with diabetes 
mellitus <16 years of age registered with the 
paediatric diabetes team. Two children in the partial 
remission phase and thus having a low total daily 
insulin dose of <0.5 units/kg/day, three children 
with Wolfram Syndrome and four children with 
Type 2 diabetes were excluded from this study. The 
two children in the partial remission phase had an 
HbA1c of 6.0% and 5.6% respectively and were 
excluded so that they would not bias the results. 
Thus, 128 children with T1DM were included in 
2013 study.  
In 2014, there were 135 children with diabetes 
mellitus <16 years of age registered with the 
paediatric diabetes team. Three children with 
Wolfram Syndrome and five children with Type 2 
diabetes were excluded from analysis of the 2014 
data. Thus, 127 children with T1DM were included 
in 2014 study.  
Table 1 outlines the number of patients on our 
database in 2013 and 2014 respectively. The 
children were divided into 3 age-groups: 0-4.9 
years, 5.0-11.9 years, 12-15.9 years. For the 
purpose of comparing results with other published 
studies the cohort of patients were also analysed in 
3 other age groups 0-10.9 years and 11-15.9 years 
(Table 2), 0-12.9 years and 13-15.9 years (Table 3) 
and less than 6 years. 
 
 
Table 1: Number of infants, children, and young people with T1DM by age band in 2013 and 2014 
 
 Age (years)  
 0-4.9 5-11.9 12-15.9 Total 
Year 2013 2014 2013 2014 2013 2014 2013 2014 
Male 1 3 43 40 29 31 73 73 
Female 2 2 30 28 23 23 55 53 
Total 3 5 73 68 52 54 128 127 
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Table 2: The mean HbA1c ± 95% CI achieved in the whole cohort, in boys and girls, and in the 2 age groups 0-
10.9  and 11-15.9 years 
 
Year 2013 2014 
Mean HbA1c(%) ± 95%CI  7.69±0.16 7.67±0.17 
Boys 7.76±0.19 7.72±0.14 
Girls 7.59±0.26 7.60±0.26 
0-10.9 years  7.53 ±0.16 7.53±0.17 
11-15.9 years 7.85±0.26 7.80±0.29 
 
Table 3: The proportion of children with T1DM in Malta who achieved target HbA1c ˂7.5%  compared to 
international data 
 
Age group (years) ˂13 13-15.9 
Year 2013 2014 2013 2014 
Total number of Maltese 
T1DM patients                   
85 87 43 40 
Proportion achieving 
HbA1c ˂7.5% in Malta 
45% 51.7% 39.5% 45% 
USA data 
(Wood et al 201310) 
27% 23% 
Swedish data 
(Samualsson et al 201311) 
60% 36% 
TEENs Study12 32% 29% 
TEENs Study13 
(European Data) 
39.4% 
 
36.5% 
 
Insulin regimen 
Over the 2-year period, 68% of participants 
were on a basal bolus regimen using insulin 
glargine and mealtime bolus doses of short-acting 
insulin. 32% were on a  twice-daily insulin regimen 
using isophane and soluble insulins. Insulin pump 
technology is not yet available in Malta. All 
patients check blood glucose levels at least 4 times 
daily with their own portable glucometer. 
 
Glycaemic control 
In 2013, the mean HbA1c achieved in our 
cohort of patients was 7.69±0.16% (61±1.75 
mmol/mol). The boys had a mean HbA1c of 
7.76±0.19% (61±2.07 mmol/mol) and the girls had 
a mean HbA1c of 7.59±0.26% (59.4±2.84 
mmol/mol). The mean HbA1c in the 0-10.9 year age 
group in this period was 7.53±0.16% (59±1.75 
mmol/mol) with a comparable mean HbA1c in boys 
of 7.51±0.23% (58.6± 2.5 mmol/mol) and in girls of 
7.55±0.28% (59±3.06 mmol/mol). The mean HbA1c 
in the 11-16 year age group in 2013 was 
7.85±0.26% (62.3±2.84 mmol/mol). The boys had a 
mean HbA1c of 8.04±0.3% (64.4±3.28 mmol/mol) 
and the girls had a better mean HbA1c of 
7.63±0.44% (60± 4.81 mmol/mol). 
In 2014, the mean HbA1c achieved in our 
cohort of patients was 7.67±0.17% (60±1.75 
mmol/mol). The boys had a mean HbA1c of 
7.72±0.14% (61±2.07 mmol/mol) and the girls had 
a mean HbA1c of 7.60±0.26% (60±2.84 mmol/mol). 
The mean HbA1c in the 0-10.9 year age group in 
this period was 7.53±0.17% (59±1.75 mmol/mol) 
with a comparable mean HbA1c in boys of 
7.54±0.18 % (59±2.5 mmol/mol) and in girls of 
7.51±0.32% (58.5±3.06 mmol/mol). The mean 
HbA1c in the 11-15.9 year age group in 2014 was 
7.8±0.29% (61.7±2.84 mmol/mol). The boys had a 
mean HbA1c of 7.9±0.39% (62.8±3.28 mmol/mol) 
and the girls had a better mean HbA1c of 7.68±0.4% 
(60.4± 4.81 mmol/mol). Table 2 summarises the 
mean HbA1c ± 95% CI achieved in the whole 
cohort, in boys and girls, and in the 2 age groups 0-
10.9  and 11-15.9 years. 
In 2013, 43.8% (95% CI 35-52%) of our 
patients achieved an HbA1c of < 7.5%                               
(˂ 58mmol/mol). 41% (95% CI 30-52%) of males 
and 47% (95% CI 34-60%) of females achieved 
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target HbA1c. Another 25% (95% CI 15-35%) of 
males and 29% (95% CI 17-41%) of females 
achieved an HbA1c of 7.5 - 8% (58-64mmol/mol). 
The percentage of patients with an HbA1c of > 
9.5% (˃ 80mmol/mol) was 4.6% (95% CI 1-8%). 
In 2014, 49.6% (95% CI 41-58%) of our 
patients achieved an HbA1c of <7.5% 
(˂58mmol/mol). 44.6% (95% CI 33-56%) of males 
and 56.6% (95% CI 43-70%) of females achieved 
target HbA1c. 18.9% (95%CI 12-26%) of our 
patients achieved an HbA1c of 7.5 - 8% (58-
64mmol/mol). The percentage of patients with an 
HbA1c of > 9.5% (˃ 80mmol/mol) was 3.9% (95% 
CI 0.6-7.3%). These results are summarised in 
Figure 1.  Figure 2 and 3 show the distribution of 
HbA1c according to age group. Table 3 and 4 
compare Maltese data with international data.  
 
 
Figure 1: Distribution of HbA1c levels according to year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Distribution of HbA1c levels according to age group 2013 
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Figure 3: Distribution of HbA1c levels according to age group 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The National Paediatric Diabetes Audit Report 
carried out by the Royal College of Paediatrics and 
Child Health using data collected by diabetes units 
in England and Wales showed that the percentage 
of children and young people with T1DM achieving 
an HbA1c of < 7.5% (< 58mmol/mol) was 15.8% in 
2012-13 and 17.1% in 2013-14.7-8 The percentage 
of children and young people with a very high 
HbA1c (greater than 80 mmol/mol) putting them at 
high risk of developing diabetic complications  has 
decreased from 25.8% in 2012/13 to 24.2% in 
2013/14. There is significant variation in levels of 
HbA1c across different units delivering care for 
infants and young people with diabetes in England 
and Wales with a mean HbA1c ranging from 8.6 to 
9% (70-75mmol/mol) in 2012-13 and from 8.5 to 
8.9% (68.9-73.6mmol/mol) in 2013-14. The mean 
HbA1c for England and Wales was 8.8% 
(73mmol/mol) in 2012-13 and 8.7% 
(71.6mmol/mol) in 2013-14.7-8 The mean HbA1c 
achieved in our cohort of patients in 2013 was 
7.69% (61mmol/mol) and in 2014 7.67% 
(60mmol/mol) (Table 4). 
 
Table 4: Maltese data compared to data from National Paediatric Diabetes audit report (England/Wales) 
2012-20137 and 2013-20148 
 Maltese data Data (England/Wales) 
2013 2014 2012-2013 2013-2014 
Mean HbA1c (%) 7.69 7.67 8.8 8.7 
Proportion achieving 
HbA1c <7.5% 
43.8% 49.6% 15.8% 17.1% 
Proportion achieving 
HbA1c 7.5-9.5% 
51.6% 
 
46.5% 58.4% 58.7% 
Proportion achieving 
HbA1c >9.5% 
4.6% 3.9% 25.8% 24.2% 
 
Data from the German/Austrian Prospective 
Diabetes Follow-up Registry (DPV) showed that an 
HbA1c of < 7.5% (˂ 58mmol/mol) can frequently be 
achieved in children with Type 1 diabetes who are 
less than 6 years of age.9 56% of children less than 
6 years of age met the recommended HbA1c goals 
of <7.5%. In our cohort of patients there were 16 
children less than 6 years of age in 2013. 10 out of 
these 16 i.e. 63% (95% CI 39-86%) achieved an 
HbA1c < 7.5% (˂ 58mmol/mol), 2 out of 16 had an 
HbA1c of 7.5-8% (58-64mmol/mol) and 4 out of 16 
had an HbA1c of > 8% (˃ 64mmol/mol). In 2014, 
there were 7 children less than 6 years of age. 5 had 
an HbA1c < 7.5%. The other 2 had an HbA1c of 
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7.6% and 8.8% respectively. 
In the United States, only 27% of children 
younger than 13, and 23% of those between 13 and 
19 years of age, meet the recommended HbA1c 
goals of < 7.5% (˂ 58mmol/mol).10 On the other 
hand, in Sweden, 60% of those younger than 13 and 
36% of individuals between 13 and 18 years had an 
HbA1c < 7.5% in 2013.
11 In Malta, 39 out of 85 ( i.e. 
45%) and 45 out of 87 (i.e. 51.7%) children with 
T1DM <13 years of age achieved an HbA1c < 7.5% 
(˂ 58mmol/mol) in 2013 and 2014 respectively. 17 
out of 43 (i.e. 39.5%) and 18 out of 40 (i.e. 45%) of 
young people with T1DM 13-16 years of age 
achieved the target HbA1c in 2013 and 2014 
respectively (Table 3).  
The TEENs study, funded by Sanofi, is one of 
the largest ever to assess T1DM management and 
the factors that affect it, including psychosocial 
parameters. The data comes from 5960 individuals 
aged 8 to 25 years seen at 219 diabetes centers in 20 
countries in the developed and the developing 
world, including Europe, the United States, Latin 
America, the Middle East, North and South Africa, 
and India. Results of the TEENs Registry Study 
were presented at the American Diabetes 
Association (ADA) 2014 Scientific Sessions by 
Professor Lori Laffel.12 Average HbA1c levels were 
8.3% for the 1724 children aged 8 to 12 years and 
8.6% for the 2854 adolescents aged 13 to 18 years. 
The proportions reaching the recommended targets 
were 32% of the younger children and 29% of the 
teens. Overall, 72% were not meeting the targets. 
18%, nearly 1 in every 5 patients, had HbA1c levels 
of 10% (86mmol/mol) or higher.12 The 2943 
European youths from 11 centers involved in the 
TEENs study had a mean HbA1c of 8.1±1.6% 
(65.0±17.5 mmol/mol).13 The mean HbA1c varied 
by age: 7.9±1.4% (62.8±15.3 mmol/mol) in the 8-
12-year age group, 8.2±1.7% (66.1±18.6 
mmol/mol) in the 13-18 year age group. One-third 
of participants achieved HbA1c targets (39.4% in the 
8-12-year age group, 36.5% in the 13-18 year age 
group). 
 
Conclusions and recommendations 
This audit report shows that glycaemic control 
achieved in Malta in infants, children and young 
people with T1DM was stable over the 2 years 
analysed.  Our results are comparable, or better, to 
that achieved in other European countries and the 
United States of America. However, there is always 
room for improvement as the Swedish data11 have 
shown, and we should continue to strive to increase 
the proportion of our patients achieving the 
recommended target HbA1c < 7.5% (˂ 
58mmol/mol). Recently, the National Institute of 
Clinical Excellence (NICE) has set even lower 
HbA1c targets of 6.5% (48mmol/mol) for young 
people with T1DM.14   
The TEENs study has identified many 
modifiable factors which significantly predict 
HbA1c target achievement.
12 These have been 
summarized in Table 5. Up to the middle of 2015, 
protocols by the Maltese Department of Health 
mandated that only isophane and soluble insulins 
could be funded for patients at the outset of T1DM 
diagnosis. Insulin analogues would only be funded 
after a minimum period of 6 months from initial 
diagnosis, and only if a number of strict clinical 
criteria were met. Since 2015, we have been 
allowed to start patients on insulin analogues from 
diagnosis. Over the last few years in our clinical 
practice, there has been a move towards 
intensification of insulin therapy including the use 
of multiple daily insulin regimens and the 
introduction of insulin dose adjustment for 
carbohydrate intake which, however, is still in its 
infancy in Malta as more input by dietitians is 
required.  
All patients are advised to check capillary 
blood glucose at least 4 times every day, and the 
overwhelming majority of our patients comply with 
this advice. Since September 2014, the number of 
blood glucose strips provided free-of-charge, for 
individuals under 18 years of age with T1DM in 
Malta, was increased to 4 per day. This reduced the 
financial burden of this essential practice and also 
served as an incentive for regular monitoring of 
capillary blood glucose levels. All of our patients 
are taught how to adjust insulin doses according to 
capillary blood glucose results so that persistent 
dysglycaemia is avoided at most times. Patients are 
also advised to contact our diabetes team if they do 
not feel confident in making any necessary 
adjustments themselves. Clinic visits are frequent, 
every 2-3 months depending on need. The 
significance of HbA1c results is explained to 
patients and treatment goals are clearly defined as 
target-setting has been shown to improve metabolic 
outcome.15 Patients with unacceptably high HbA1c 
levels are admitted to hospital for a short period to 
stabilise their blood glucose. During their in-patient 
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stay they meet with the diabetes multidisciplinary 
team to re-inforce diabetes education. A clinical 
guideline on how to treat patients with a high HbA1c 
will be formulated and put into practice.  
 
Table 5: Factors significantly predicting HbA1c target achieved from TEENs study
12 
 
Demographic factors p˂0.001 
Absence of financial burden related to T1DM 
management 
 
Shorter T1DM duration  
Age ˂12 years  
Treatment factors p≤0.005 
Pump therapy  
Blood glucose monitoring ˃3 times daily  
CHO counting  
Exercise ˃30 minutes/week  
No history of DKA in the past 3 months  
Family factors p˂0.019 
Parental involvement in T1DM care  
Absence of diabetes specific family conflict  
Living with 2 parents in the home  
 
In the coming year, we would wish to start 
organising multidisciplinary team (MDT) meetings 
to discuss patients who are not achieving the 
recommended treatment goals on an individual 
basis. The aim of these meetings is to come up with 
an individual care plan to help such patients 
improve glycaemic control: changing the insulin 
regimen, reinforcing structured diabetes education, 
offering support to the family/patient to help them 
in self-management tasks, telephone contact in 
between clinic visits, psychological help, 
identifying psychosocial dysfunction within 
families and enrolling the help of 
psychologist/social worker to work through the 
issues.  We do not have these MDT meetings 
regularly as yet because of a significant lack in 
human resources, especially with regard to diabetes 
nursing staff. This shortage in human resources 
needs to be addressed by the Department of Health 
and our hospital’s administration. 
We need to set up a formal annual review so 
that all of the seven key processes of diabetes care: 
HbA1c, BMI, blood pressure, urinary albumin, lipid 
screening, eye screening, and foot examination are 
done regularly and systematically as stipulated by 
international guidelines.5,14 The audit data, 
including also acute complications such as diabetic 
ketoacidosis and severe hypoglycaemia, will be 
collected and analysed annually to assess whether 
the changes implemented have resulted in an 
improvement in outcome for children and 
adolescents with T1DM in Malta. 
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